Crosstalk between estrogen receptor (ER) and the inflammatory nuclear factor κB (NFκB) pathway in ER+ breast cancers may contribute to a more aggressive phenotype. Pleckstrin Homology-Like Domain, Family A, member 1 (PHLDA1), a target gene of ER-NFκB crosstalk, has been implicated in cell survival and stem cell properties. 17β-estradiol (E2), acting through ERα, and pro-inflammatory cytokines, acting through NFκB, increase the nascent transcript and PHLDA1 messenger RNA stability, indicating both transcriptional and post-transcriptional control of PHLDA1 expression. We show that PHLDA1 is a direct target of miR-181 and that mature miR-181a and b, as well as their host gene, are synergistically downregulated by E2 and tumor necrosis factor α, also in an ER-and NFκB-dependent manner. Thus, ER and NFκB work together to upregulate PHLDA1 directly through enhanced transcription and indirectly through repression of miR-181a and b. Previous studies have suggested that PHLDA1 may be a stem cell marker in the human intestine that contributes to tumorigenesis. Our findings that PHLDA1 is upregulated in mammospheres (MS) of ER+ breast cancer cells and that PHLDA1 knockdown impairs both MS formation and the expansion of aldehyde dehydrogenase (ALDH)-positive population, suggest that PHLDA1 may play a similar role in breast cancer cells. Upregulation of PHLDA1 in MS is largely dependent on the NFκB pathway, with downregulated miR-181 expression a contributing factor. Over-expression of miR-181 phenocopied PHLDA1 knockdown and significantly impaired MS formation, which was reversed, in part, by protection of the PHLDA1 3′ untranslated region (UTR) or overexpression of PHLDA1 lacking the 3′UTR. Furthermore, we find that elevated PHLDA1 expression is associated with a higher risk of distant metastasis in ER+ breast cancer patients. Altogether, these data suggest that high PHLDA1 expression is controlled through an ER-NFκB-miR-181 regulatory axis and may contribute to a poor clinical outcome in patients with ER+ breast tumors by enhancing stem-like properties in these tumors.
INTRODUCTION
Nearly 75% of breast tumors express estrogen receptor α (ER) and will be treated with endocrine therapy, such as tamoxifen or aromatase inhibitors. Yet, about 50% of these tumors fail to respond and eventually recur as aggressive, metastatic cancers. Activation of nuclear factor κB (NFκB) is thought to be a potential driver of an aggressive phenotype, since it promotes tumor growth, cell survival, adhesion/migration/invasion, angiogenesis and drug resistance. Indeed ER+ tumors with a high risk of recurrence have constitutive activation of the NFκB pathway 1 and constitutive activation of NFκB in ER+ tumors is associated with endocrine and chemotherapy resistance. 2, 3 Furthermore, inhibition of NFκB signaling has been shown to restore sensitivity to endocrine therapy in several preclinical models of resistance. 4, 5 The underlying mechanisms on how NFκB activation in ER+ breast cancer influences poor outcome are not fully understood, but recent evidence has suggested that crosstalk between ER and NFκB may be a contributing factor. Until recently, the paradigm in the field was that ER and NFκB repress each other's transcriptional activity, however, we have shown that these two factors can work together to upregulate a gene signature associated with luminal B tumors and poor response to tamoxifen. 6 This is clinically significant because luminal B tumors tend to be aggressive, resistant to therapy, recur earlier, and are associated with an overall poor patient outcome.
One major feature of the gene signature regulated by ER-NFκB crosstalk is cell survival, as illustrated by Baculoviral IAP Repeat Containing 3 (BIRC3) and Pleckstrin Homology-Like Domain, Family A (PHLDA1), member 1. In previous studies, we established that BIRC3 is essential for estrogen-dependent breast cancer cell survival. 7 However, the function of PHLDA1 in ER+ breast cancer is less clear. PHLDA1 was described as a pro-survival factor by playing an important role in the anti-apoptotic effects of IGF-1 in breast cancer cells. 8 More recently, PHLDA1 has been described as an epithelial stem cell marker in the human small and large intestine 9 that contributes to tumorigenesis. In breast cancer, factors and pathways that drive survival, maintenance, and propagation of stem-like cells, which are often termed cancer stem cells (CSCs), are biologically and therapeutically important, given that CSCs are thought to be responsible for therapy resistance and tumor recurrence. Interestingly, luminal B tumors show the most overlap with CSC markers compared with other ER+ tumors. 10, 11 Therefore, PHLDA1's position at the intersection of pro-survival signaling and stem-like cell properties prompted us to explore its regulation by ER-NFκB crosstalk and its function in ER+ breast cancer in greater detail.
RESULTS

Transcriptional and post-transcriptional regulation of PHLDA1 by ER and NFκB
To understand regulation of PHLDA1 by ER and the NFκB pathway, ER+ MCF-7 breast cancer cells were treated with 17β-estradiol (E2) in combination with pro-inflammatory cytokine tumor necrosis factor α (TNFα) to induce activation of the NFκB pathway. As previous data suggested, 6 the combination of E2 and TNFα results in the upregulation of both PHLDA1 messenger RNA (mRNA) and protein (Figures 1a and b) . Similarly, E2 combined with interleukin-1β (IL-1β), another pro-inflammatory cytokine that activates NFκB pathway, results in PHLDA1 upregulation, while E2 in combination with IL-6, which cannot activate NFκB, has no effect on PHLDA1 expression ( Supplementary Figure 1) . The effect of E2+TNFα is mediated by both ER and the NFκB pathway since silencing ER via small interfering RNA (siRNA), blocking ER activity through the use of the antagonist ICI182,7808 (ICI), or inhibiting the NFκB pathway with a small molecule pan-Inhibitory κB Kinase (IKK) inhibitor (IKK7), which targets both IKKα and IKKβ, attenuated E2+TNFα action on both PHLDA1 mRNA ( Figure 1a ) and protein ( Figure 1b ).
The role of the NFκB pathway was explored further in an alternative, cytokine-independent system that utilizes doxycycline-inducible constitutively active IKKβ. Expression and activity of constitutively active IKKβ is shown in Supplementary  Figures 2a and b , respectively. We find that the combination of E2 and doxycycline is sufficient to drive PHLDA1 expression to a greater extent than either E2 or doxycycline alone ( Supplementary  Figure 2c ), suggesting that interaction between ER and the canonical NFκB pathway controls PHLDA1 expression in ER+ breast cancer cells.
Primers designed to detect nascent, unprocessed primary transcripts of PHLDA1 show that E2 and TNFα upregulate PHLDA1 transcription ( Figure 1c ), also in an ER-and NFκB-dependent manner. However, we also find that the combination of E2 and TNFα increased the stability of PHLDA1 mRNA by extending its half-life from an estimated 1 h to more than 2 h following actinomycin D treatment ( Figure 1d ). This suggests that E2 and TNFα regulate PHLDA1 expression through both transcriptional and post-transcriptional mechanisms.
Since microRNAs (miRs) can control mRNA stability, a bioinformatic search for putative miR-target gene pairs (TargetScan.org) was conducted. PHLDA1 was predicted to be a putative target of miR-181 family ( Supplementary Figure 3a ) because there is an exact match between the PHLDA1 3'UTR positions 357-364 and positions 2-8 of the mature miR-181. To determine whether miR-181 can target PHLDA1, miR-181a and b synthetic mimics were transfected into MCF-7 cells. Following E2 and TNFα treatment, we find that both mimics, either alone or in combination, attenuated the expression of both PHLDA1 mRNA ( Figure 2a ) and protein ( Figure 2b ). This effect was confirmed in another ER+ cell line T47D ( Supplementary Figure 3b ). To demonstrate that miR-181a and b specifically target the miR-181 site in PHLDA1's 3′UTR, target protector technology was utilized. 12 Target protectors are single-stranded, modified RNAs that specifically interfere with the interaction of the miR with the 3′UTR of a single target, while leaving the regulation of other targets of the same miR unaffected. Numerous recent publications have successfully utilized protector technology to demonstrate the miR-target gene pair relationship. [13] [14] [15] [16] As shown in Figure 2c , the miR-target protector designed to prevent miR-181 binding to PHLDA1's 3′UTR region reversed the inhibition of miR-181a+b mimics on PHLDA1 expression in a dose-dependent manner. This protector is specific for PHLDA1, because on another miR-181 target gene, Bcl-2, 17 the PHLDA1-miR-181 protector has no effect ( Supplementary Figure 3c ). Together these results indicate that PHLDA1 is a direct target of miR-181a and b.
E2 and TNFα repression of miR-181a and b contributes to PHLDA1 upregulation miR-181a and b are arranged in a bicistronic manner as part of a non-protein coding RNA that was recently annotated as miR-181A1 host gene (HG) in chromosome 1. A previous report in the literature suggested that E2 downregulates miR-181a and b expression; 18 however, regulation of the HG has not been explored. Our studies indicate that E2 treatment of MCF-7 cells reduces the expression of miR-181A1 HG, as well as mature miR-181a and b ( Figure 3 ). Use of ICI ( Figure 3b ) or siERα ( Supplementary Figure 4) to probe the role of ER in miR-181A1 HG expression, suggests that ER is not only required for E2-dependent downregulation but that unliganded ER may be exerting a baseline repression of the gene.
Interestingly, TNFα also downregulates miR-181A1 HG expression and the combination of E2+TNFα resulting in a further repression, compared with either E2 or TNFα alone (Figures 3a and d). A similar effect was observed in additional ER+ cell lines (Supplementary Figure 5 ). In addition, IKK7 prevented downregulation of miR-181A1 HG indicating a role for the NFκB pathway as well ( Figure 3c ). While an effect of TNFα alone on miR-181a and b levels was not consistent or significant (data not shown), a more rapid and robust downregulation of mature miR-181 levels was observed with E2+TNFα than with E2 alone (see 2 h time points in Figures 3e and f). The faster reduction of mature miR-181a and b by E2+TNFα is consistent with the timescale for PHLDA1 upregulation and mRNA stabilization. This data suggests a model where E2 and TNFα repress transcription of the HG, which leads to a reduction in both mature miR-181 family members.
To determine the extent to which the downregulation of endogenous miR-181 may contribute to PHLDA1 upregulation, two approaches were taken. First, cells were treated with actinomycin D in the presence or absence of the PHLDA1-miR-181 target protector. As indicated in Figure 4a , PHLDA1 mRNA is elevated over twofold by the protector and confirms that PHLDA1 mRNA stability is controlled by endogenous miR-181. Second, overexpression of anti-miR-181a and b inhibitors elevates baseline PHLDA1, as well as TNFα-induced PHLDA1 expression ( Figure 4b ); this is similar to the protector effect shown in Figure 4a . Altogether, this data indicates that the downregulation of endogenous miR-181a and b may contribute to the posttranscriptional regulation of PHLDA1 expression. Together, these findings suggest that E2 and TNFα act synergistically, via ER and NFκB, to upregulate PHLDA1 expression not only at the transcriptional level but also at a post-transcriptional level by reducing miR-181a and b expression. PHLDA1 is upregulated in mammospheres (MS) of ER+ breast cancer cells and is required for MS formation and growth Given the role of PHLDA1 in intestinal stem cells and tumorigenesis, 9 we decided to investigate the functional role of PHLDA1 in ER+ cancer cell MS, which are known to be enriched with breast CSCs. 19 The MS assay exploits the unique property of stem/progenitor cells to survive and grow in serum-free suspension, while more differentiated cells undergo anoikis and die in these conditions. 20 Additionally, MS culture enriches for cells with enhanced metastatic character, that are highly tumorigenic, and that are chemo-and radio-resistant, [21] [22] [23] [24] and therefore represent a good model system to study breast CSCs. In a panel of ER+ breast cancer cells, we find that PHLDA1 mRNA ( Figure 5a ) and protein (Figure 5b ) are upregulated in MS cultures when compared with cells grown in standard, adherent monolayer cultures (2D). While it is possible that PHLDA1 may be regulated by MS media, we were unable to test this since culture of adherent monolayer of cells with MS media resulted in morphology changes and eventual cell death, possibly due to serum withdrawal (Supplementary Figure  6a ). However, our finding that PHLDA1 is upregulated in MS because of CSC content rather than the media formulation is consistent with the report by Murohashi et al. 25 Their work showed that PHLDA1 gene expression is enriched in the CSC population, as identified by CD44 high /CD24 low surface marker expression, in multiple breast cancer cell lines, including MCF-7, HCC70 and HCC1954. 25 Because the NFκB pathway is active and required for the survival of breast CSCs, 26, 27 we postulated that this pathway might also have a role in regulating PHLDA1 expression in MS. Treatment with IKK7 significantly reduced PHLDA1 expression in MS while ER-blockers such as ICI, 4-hydroxytamoxifen (4OHT) and desmethylarzoxifene (DMA) had no effect on PHLDA1 expression ( Figure 5c ). In addition, expression of miR-181A1 HG and mature miR-181b but not miR-181a was significantly lower in MS than 2D cultures (Figure 5d ). Together, these findings suggest that high intrinsic NFκB activity and reduced miR-181b levels contribute to elevated PHLDA1 expression in ER+ breast cancer cells grown as MS.
To examine the potential role of PHLDA1 in MS formation and growth, we transfected MCF-7 cells with siRNA targeting PHLDA1 or control siRNA (siNeg) in standard 2D cultures and then seeded single cells in MS conditions. Efficiency of siPHLDA1 knockdown is shown in Supplementary Figure 6b . Silencing PHLDA1 results in attenuated MS formation and growth shown by a reduction in both the number of MS formed and MS size, respectively (Figures 6a and b and Supplementary Figure 6c ). Yet, silencing PHLDA1 has no significant effect on cell viability in standard adherent monolayer cultures ( Supplementary Figure 6d) , suggesting that PHLDA1 might have an essential role in the survival and maintenance of ER+ breast CSCs. To corroborate this finding, an additional breast CSC marker was utilized. ALDH activity assessed by the Aldefluor assay is used to identify cells with CSC-like properties. 28 E2 treatment is known to expand the breast CSC population, 29 hence we utilized E2 together with TNFα treatment on MCF-7 cells and probed for the role of PHLDA1. The increased ALDH-positive population resulting from E2+TNFα treatment is significantly attenuated with siPHLDA1 ( Figures 6c and d) , further supporting an essential function for PHLDA1 in ER+ breast CSCs.
To confirm the role of PHLDA1 in CSCs, miR-181a and b mimics, which reduce PHLDA1 expression (see Figure 2 ), were transfected into MCF-7 cells prior to seeding in MS assays. Like siPHLDA1, miR-181a+b mimics attenuated MS formation, and addition of the miR-181 target protector for PHLDA1 partially reversed this effect (Figure 6e ). To further confirm that miR-181 targeting of PHLDA1's 3′UTR contributes to MS formation, we performed a rescue experiment in which we over-expressed PHLDA1 lacking the 3′ UTR ( Supplementary Figure 6e) ; hence, miR-181a and b are unable to target it. MS formation of PHLDA1 over-expressing cells is not statistically different from that of vector control cells (Figure 6f ). However, in the presence of miR-181a and b mimics, attenuated MS formation is partially restored by PHLDA1 overexpression (Figure 6f ). The partial effect of the PHLDA1-miR-181 target protector and PHLDA1 overexpression may be explained by the fact that miR-181a and b have additional targets, such as Bcl-2 ( Supplementary Figure 3c ), which could also be involved in MS formation. Together, these findings suggest that targeting of PHLDA1 in MS by miR-181a and b leads to attenuated MS formation, similar to silencing of PHLDA1, and further supports a role for the PHLDA1-miR-181 axis in controlling MS formation of ER+ breast cancer cells.
High PHLDA1 expression predicts poor clinical outcome in patients with ER+ breast cancers
To examine the clinical relevance of PHLDA1 expression in breast tumors, we analyzed publically available patient datasets to determine whether PHLDA1 mRNA expression is correlated with clinical outcome. While there is no significant association between PHLDA1 and patient outcome when all breast cancer patients are examined (Figure 7a ), elevated PHLDA1 expression is significantly associated with a higher risk of distant metastasis in patients with ER+ breast cancers (Figure 7b) . The opposite is observed in patients with ER − breast cancers (Figure 7c ). This finding suggests that not only is PHLDA1 expression a potential predictor of metastasis and aggressiveness in ER+ tumors, but also that it may have different functions in ER+ vs ER-breast tumors. 
DISCUSSION
In this study, we have elucidated a unique ER-NFκB-miR-181 regulatory loop that controls expression of PHLDA1 in ER+ breast cancer cells. More specifically, we showed that E2, acting via ER, and TNFα, acting via the NFκB pathway, work together to increase both transcription and stability of PHLDA1 mRNA (Figure 8) . Furthermore, we have demonstrated that ER and NFκB working together to synergistically suppress expression of miR-181a and b, both of which directly target PHLDA1, to enhance PHLDA1 mRNA stability. Thus, a regulatory loop between ER, NFκB and miR-181 demonstrates a concerted, highly coordinated mechanism to control the ultimate expression levels of the PHLDA1 gene. In addition to its regulation, we show that PHLDA1 has an important role in the formation and growth of ER+ MS, which enriches for cells with stem-like/progenitor properties, and the expansion of the ALDH-positive population. These findings indicate an essential function for PHLDA1 in bestowing CSC-like properties to ER+ cells and may contribute to the association between elevated PHLDA1 expression and poor outcome in patients with ER+ breast cancers. . Model for PHLDA1 regulation and function in ER+ breast cancer cells. ER and NFκB work together to regulate PHLDA1 through a direct transcriptional mechanism and an indirect, posttranscriptional mechanism that involves downregulation of miR-181. High PHLDA1 expression and low miR-181a/b is essential for CSClike properties. In turn, this may lead to an aggressive breast cancer phenotype and a poor patient outcome.
Previous work from our lab showed that positive crosstalk between ER and NFκB can upregulate a number of genes associated with an aggressive breast cancer phenotype. 6, 30 In general, this crosstalk has been shown to involve cooperative ER and p65 recruitment to gene promoters resulting in transcriptional synergy. [31] [32] [33] Previous work has suggested that the upstream region of the PHLDA1 gene (also known as TDAG51) is complex with a bidirectional promoter arrangement. 34 Although this region contains an NFκB responsive element, we have been unable to identify a clear transcriptional regulatory mechanism or consistent ER/NFκB binding within 50 kb of the human PHLDA1 gene. Intriguingly, we have found that ER and NFκB also work together to synergistically downregulate expression of the miR-181 HG. To our knowledge, this is the first instance of these factors working cooperatively to repress gene expression and investigation into the mechanism is ongoing.
Our results demonstrate that both PHLDA1 and miR-181 have a role in the formation and growth of MS. Understanding the underlying mechanisms and molecular drivers of breast CSCs is important because CSCs are endowed with tumorigenic potential, are chemo-and radio-resistant, display an enhanced metastatic phenotype, and are thought to be responsible for recurrence. 21, 22, 24, [35] [36] [37] Hence, one way ER and NFκB may contribute to aggressive breast cancers is through upregulation of PHLDA1 to enhance a CSC phenotype. Interestingly, downregulation miR-181b also appears to be necessary for CSC phenotype, partially by targeting PHLDA1. However, our findings are somewhat contradictory to the published roles of both PHLDA1 and miR-181 in breast cancer. PHLDA1 was identified as a direct substrate and mediator of Aurora A kinase action in ER − MDA-MB-231 breast cancer cells, and PHLDA1 loss was described as a bad prognostic factor. 38 Similarly, numerous publications showing elevated miR-181 family members is associated with a worse phenotype and worse prognosis in breast cancer. However, this typically applies to ER − breast cancers. [39] [40] [41] For example, upregulation of miR-181a by tumor growth factor β was significantly associated with metastatic disease in ER − breast cancers. 39 However, ER+ and ER − tumors represent two very distinct disease states. Other functional partners of PHLDA1 that may differentially modulate its activity in ER+ vs ER − remain to be identified. This type of context-specific protein function is not unprecedented; other factors, such as Notch1 and c-Myb, were shown to behave as either tumor suppressors or oncogenes depending on the disease type or marker status. 42, 43 Since high expression of PHLDA1 is correlated with poor patient outcome in ER+ cancers and low expression is correlated with poor outcome in ER − cancers, our results suggest that these inconsistencies may be resolved if we consider the roles of PHLDA1 and miR-181 as context specific.
In conclusion, we determined that ER and NFκB factors work together to upregulate PHLDA1 and simultaneously repress miR-181a and b expression in ER+ breast cancer cells, leading to amplified expression of the ER-NFκB-miR-181 target gene, PHLDA1. The inverse, dichotomous nature of low miR-181 and high PHLDA1 expression, in turn contributes to survival and growth of breast CSCs. Together, these findings suggest that ER and NFκB crosstalk can mediate an aggressive phenotype by controlling gene regulatory loops that can impact on breast CSCs.
MATERIALS AND METHODS Reagents
E2, 4OHT and actinomycin D were purchased from Sigma (Milwaukee, WI, USA). TNFα, IL-1β, and IL-6 were obtained from R&D Systems (Minneapolis, MN, USA). ICI182,780 (ICI) was purchased from Tocris (Bristol, UK). The NFκB inhibitor, IKK7, was purchased from EMD Millipore (Mahopac, NY, USA). The PHLDA1 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) (sc-23866) and the β-actin antibody from Sigma (St Louis, MO, USA) (A5441). DMA was generously provided by Dr Gregory Thatcher (UIC, Chicago, IL, USA). siRNA targeting ERα or PHLDA1 or a nonspecific control (siNeg) was purchased from Ambion (Grand Island, NY, USA). PHLDA1 miScript target protector for miR-181 and miR-181a and b synthetic mimics were purchased from Qiagen (Valencia, CA, USA). Anti-miR-181a and b inhibitors were purchased from Ambion.
Cell and MS culture
Human ER+ breast cancer cell lines, MCF-7, T47D and BT474, were obtained from Dr Debra Tonetti (UIC) and routinely maintained in Roswell Park Memorial Institute medium (RPMI) 1640 (Invitrogen Life Technologies, Grand Island, NY, USA) with phenol red supplemented with 10% fetal bovine serum, 1% non-essential amino acids, 2 mM L-glutamine, 1% antibiotics penicillin-streptomycin and 6 ng/ml insulin. Prior to treatment with ER ligands and/or cytokines, cells were cultured in phenol red-free media supplemented with 5% charcoal-dextran-stripped fetal bovine serum for 2-3 days prior to treatment. For MS, breast cancer cells were seeded at single-cell density in low attachment plates in media described by Dontu et al., 44 supplemented with 1% methyl cellulose to prevent cellular aggregation. 45 After 7 days, the diameter of MS was measured and MS ⩾ 75 μm in diameter were counted. For RNA measurements, MS were grown for 7 days and inhibitors were added for the last 6-24 h prior to RNA isolation.
Plasmids, lentiviral transduction and stable PHLDA1 overexpressing cell line
The lentiviral expression vector for PHLDA1 or the empty vector control (pLX304) were purchased from DNASU [46] [47] [48] (Tempe, AZ, USA) and Addgene (Cambridge, MA, USA) (plasmid 25890), respectively. 49 Briefly, 23 μg of PHLDA1 or vector plasmid, 15 μg of packaging plasmid (psPAX2) and 8 μg of envelope plasmid (pMD2.G) were used to transfect packaging cells (293FT) with polyethylenimine. Packaging plasmid and envelope plasmid were a generous gift from Dr Chong Wee Liew (UIC). PHLDA1 overexpressing or vector control cell lines were generated by transducing MCF-7 cells with lentiviral particles and blasticidin (10 μg/ml) selection for 2 weeks. siRNA and miRNA Transfections siERα, siPHLDA1, miR-181a and b mimics or anti-miRs, and PHLDA1 target protector were transfected as previously described. 7 Experiments were carried out 48 h after transfection.
Western blot
Whole-cell extracts were prepared using M-PER (Thermo Scientific, Rockford, IL, USA). Proteins were separated by SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose membranes (Thermo Scientific), blocked for 1 h in buffer containing 5% nonfat dry milk (Lab Scientific, Highlands, NJ, USA) or 5% bovine serum albumin, and incubated with the appropriate primary antibody overnight. The next day, secondary antibody was applied and the signal was visualized on a Molecular Imager ChemidocXRS (Bio-Rad Laboratories, Hercules, CA, USA) using the Pierce Supersignal West Pico chemiluminescent substrate (Thermo Scientific).
RT-quantitative PCR
Total RNA was isolated and quantitative PCR performed as described previously. 6 Fold change was calculated using the ΔΔCt method with 36B4 serving as the internal control. Quantitative PCR primer sequences are available upon request. For miRNA analysis, RNA was reverse transcribed using the miRCURY LNA Universal RT kit (Exiqon, Woburn, MA, USA) and quantitative PCR using LNA PCR primers sets (Exiqon) was run according to manufacturer's guidelines. RNU44 and RNU48 served as internal controls.
MTS cell viability assay
CellTiter96 AQueous One Solution (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS)) assay kit was purchased from Promega (Madison, WI, USA) and MTS viability assay was run according to manufacturer's guidelines.
